145 related articles for article (PubMed ID: 19317268)
1. Carcinosarcomas of the uterus and ovary: a clinicopathologic and immunohistochemical study of 11 cases.
Kondi-Pafiti A; Grapsa D; Hasiakos D; Gennatas K; Fotiou S
Eur J Gynaecol Oncol; 2009; 30(1):93-7. PubMed ID: 19317268
[TBL] [Abstract][Full Text] [Related]
2. Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas.
Costa MJ; Morris RJ; Wilson R; Judd R
Hum Pathol; 1992 Jul; 23(7):787-97. PubMed ID: 1612579
[TBL] [Abstract][Full Text] [Related]
3. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases.
Costa MJ; Khan R; Judd R
Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102
[TBL] [Abstract][Full Text] [Related]
4. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
5. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
6. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
7. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.
Schipf A; Mayr D; Kirchner T; Diebold J
Virchows Arch; 2008 Mar; 452(3):259-68. PubMed ID: 18193277
[TBL] [Abstract][Full Text] [Related]
9. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
Veras E; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
[TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
11. [Carcinosarcoma of the uterus and ovaries].
Iakovleva IA; Shendereva TS
Arkh Patol; 1978; 40(4):59-65. PubMed ID: 678156
[TBL] [Abstract][Full Text] [Related]
12. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics.
Kedzia W; Pruski D; Iwaniec K; Przybylski M; Friebe Z; Rajpert-Kedzia H
Folia Histochem Cytobiol; 2012; 50(4):513-8. PubMed ID: 23264213
[TBL] [Abstract][Full Text] [Related]
13. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
15. Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter study.
Rosati A; Vargiu V; Certelli C; Arcieri M; Vizza E; Legge F; Cosentino F; Ferrandina G; Fanfani F; Scambia G; Corrado G
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6479-6488. PubMed ID: 36773091
[TBL] [Abstract][Full Text] [Related]
16. Carcinosarcoma of the uterus in advanced stage: a case report.
Tasic L; Vasiljevic M; Prorocic M; Jurisic A; Dragojevic-Dikic S; Jankovic-Raznatovic S
Eur J Gynaecol Oncol; 2013; 34(4):343-6. PubMed ID: 24020144
[TBL] [Abstract][Full Text] [Related]
17. Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation.
Gilcrease MZ; Delgado R; Albores-Saavedra J
Arch Pathol Lab Med; 1998 Oct; 122(10):907-11. PubMed ID: 9786352
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
19. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis.
Sreenan JJ; Hart WR
Am J Surg Pathol; 1995 Jun; 19(6):666-74. PubMed ID: 7755153
[TBL] [Abstract][Full Text] [Related]
20. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
